Accelovance
Exhibitor
Accelovance is a vaccine-focused Contract Research Organization (CRO) supporting clients’ development needs by leveraging its operational knowledge and success in vaccine trials and patient recruitment. Unique in comparison to most CROs, Accelovance provides complete clinical trial understanding and expertise by leveraging the experience of its CRO staff as well as the knowledge gained from its investigative site network subsidiary, Optimal Research (Optimal). Optimal is comprised of six wholly-owned vaccine-focused dedicated research centers, in addition to operating an extended oncology and pediatric site network. Providing an integrated CRO and site solution enhances operational performance, streamlines project timelines, and optimizes financial requirements.
Accelovance and Optimal have managed more than 170 Phase I-IV vaccine studies (including pivotal vaccine programs) for biotech, pharma, government, and non-profit organizations. The value of Accelovance’s services and clinical execution have been recognized by the World Vaccine Congress naming Accelovance “Best CRO” Vaccine Industry Excellence (ViE) Award in 2009, 2010, and 2011 by colleagues in the industry. Accelovance’s site network was also honored in 2014 with the Highly Recommended award for “Best Clinical Trial Site or Network”.
Accelovance and Optimal have managed more than 170 Phase I-IV vaccine studies (including pivotal vaccine programs) for biotech, pharma, government, and non-profit organizations. The value of Accelovance’s services and clinical execution have been recognized by the World Vaccine Congress naming Accelovance “Best CRO” Vaccine Industry Excellence (ViE) Award in 2009, 2010, and 2011 by colleagues in the industry. Accelovance’s site network was also honored in 2014 with the Highly Recommended award for “Best Clinical Trial Site or Network”.
sponsors
co-located with